Epi One

In this clip from the Test. Optimize. Scale. podcast, our CEO Michael Marquardt explains how Epi One is built on the merging of the medical and computational technology fields. He also talks about the unique perspective and knowledge that our founder Dr Sophia Fang brings to the table, and why Epi One is unique on the field of cancer diagnostics. You can find the show wherever you normally listen to podcasts.

We are thrilled to announce that the scientific genius behind Epi One, Dr Sophia Fang, will be joining our CEO, Michael Marquardt, for a very special webinar on November 26th. Together they'll be covering exactly how our technology works to detect cancer early, accurately and cost-effectively, and they'll be looking at our development timeline and milestones. This is a fantastic opportunity to hear from one of the leading scientific minds in the cancer detection space ahead of the closing of our crowdfunding round on December 4th. Register at https://lnkd.in/eqjw3YJh

As our crowdfunding round starts to draw to a close, a few words from Michael Marquardt, our CEO...

What if we could detect cancer before symptoms appear, potentially saving millions of lives? At Epi One, we're not just imagining this future - we're building it. Our approach could significantly impact healthcare. There is a critical need for early cancer detection and so we're addressing one of its most pressing issues. Our DNA-based biomarker method is also innovative. It enables us to focus on the trifecta of earlier AND more accurate AND more affordable cancer detection. And our team is led by world-class scientists, who bring leading edge expertise to this challenge. But the most exciting part for you is that YOU can be part of this potential healthcare transformation. Join our crowdfunding campaign before it's too late at https://lnkd.in/eYrJiFKJ

Having the right environment to nurture innovation and growth is crucial for us at Epi One. And SUNY Downstate's Biotech Incubator offers us access to cutting-edge laboratory facilities, ensuring that we can conduct our groundbreaking research in cancer detection without the limitations often faced by early-stage biotech companies. Having our lab space here gives us access to the vast resources of SUNY Downstate Medical Center, an ecosystem that provides Epi One with a wealth of knowledge, expertise, and resources that would be challenging and costly to acquire independently. The incubator environment fosters networking and collaboration, and this setup also allows us to allocate more resources to research and development rather than facility management. In short, securing lab space at the Downstate Biotechnology Incubator represents a significant strategic advantage. Our crowdfunding campaign with StartEngine ends in just two weeks' time. Don't miss out on being a part of this revolution!

Epi One CEO Michael Marquardt was recently invited on to the Test. Optimize. Scale. podcast to talk about what we're doing here at Epi One. In this clip he discusses why he is so passionate and driven to ensure that we succeed in our mission. You can find the show wherever you normally listen to podcasts.

We are thrilled to share with you that our equity crowdfunding campaign has now reached the?$1.5 million?mark. This moves us closer to our goal of advancing early cancer detection technology and, in total, we have now raised more than?$4.6 million. With only 19 days?remaining in our offering, this is an opportunity to join over 300 investors who believe in our mission to support early, accurate cancer diagnosis and treatment. Join them now via the link below ??

Hope. That's what we have. Hope that what we're building at Epi One will make cancer less formidable and more manageable in the future. Hope that the community that you are a part of is the start of a movement that makes cancer diagnosis more accurate, more affordable and more effective. Hope that you might consider investing in our mission via our Start Engine campaign page. As things stand right now we've raised $1.492 million. It'd be amazing to hit the $1.5 million mark. There are now just 20 days left before the round closes. If you share our sense of hope, please take a look at the crowdfunding page at https://lnkd.in/eYrJiFKJ

Tomorrow at 4.30pm EST Michael Marquardt, our CEO, will be sitting down with Daniel A. Etra, one of our lead investors, for a fireside chat about exactly what we're doing at Epi One. Daniel has almost three decades of successful international business experience, and has deep industry experience in healthcare and technology, as well as strategy, and operational expertise building and scaling businesses. The event will cover: > how we’re transforming our innovations into real-world applications that can help patients > what sets us apart from others in the cancer diagnosis marketplace > the role of hope and how it fuels our work and the impact we aim to make > the latest developments at Epi One We'll also be holding an open Q&A session; your chance to ask anything you want, whether you're curious about our technology or our mission. You can register via the link below. We hope to see you there!